


# BIOTARGET™

Advanced xeno-free medium for the activation and expansion of T cells



- Serum-free, xeno-free media
- cGMP-manufactured
- High viability and expansion
- Simple, reliable protocols

## Advancing research and clinical applications

Immunotherapy is at the forefront of state-of-the-art biological advances in treatments and cures for disease. Standardizing the research that creates breakthroughs in this field and elucidating the complex cellular interactions involved in immune response will require advanced, consistent, and carefully developed tools. With over 35 years of experience in cell culture media development, Biological Industries (BI) has created **BIOTARGET™ Medium**, specifically optimized for culturing T cells and other peripheral blood mononuclear cells (PBMCs) to advance the future of immunotherapy.

BIOTARGET™ is a defined, serum-free, xeno-free formulation which enables excellent fold expansion and is manufactured under cGMP conditions.

#### **Applications**

- LAK/TIL/CAR-T generation and expansion
- T cell activation
- Cytokine production
- Culturing peripheral blood mononuclear cells (lymphocytes and monocytes)
- T cell subset-specific responses
- NK cell generation and tumor recognition
- Macrophage activation

#### High viability and expansion rates

#### 




Figure 1: Expansion and viability of T cells. Tumor Infiltrating T Lymphocytes (TILs) were expanded in BIOTARGET<sup>™</sup> or competitor medium supplemented with IL-2 for 14 days. Medium added on day 0, 5 and 7 contained 5% human AB serum. BIOTARGET<sup>™</sup> shows excellent **A**. fold expansion and **B**. viability compared to competitor.

### T cell phenotype and activity assays




Figure 2: Maintaining T cell phenotype and biological activity. Tumor Infiltrating T Lymphocytes (TILs) were expanded in BIOTARGET™ or competitor medium for 14 days. Cells were then analyzed by FACS analysis or co-cultured with HLA-matched melanoma cells and tested for IFN-y secretion. BIOTARGET™ showed increased A. CD8 expression and B. IFN-y secretion in comparison to the competitor.

ORDERING INFORMATION		
PRODUCT	CAT.#	SIZE
BIOTARGET™ Medium	05-080-1A	500 mL
PLTGold® Human Platelet Lysate (Research-grade)	PLTGOLD27R PLTGOLD100R PLTGOLD500R	27 mL 100 mL 500 mL
PLTGold® Human Platelet Lysate (Clinical-grade)	PLTGOLD27GMP PLTGOLD100GMP PLTGOLD500GMP	27 mL 100 mL 500 mL
NutriFreez™ D10 Cryopreservation Medium	05-713-1E 05-713-1B 05-713-1A	50 mL 100 mL 500 mL

Biological Industries USA | T. 860.316.2702 F. 860.269.0596 | orders@bioindusa.com

 $@2019 \ Biological \ Industries \ USA, Inc. \ All \ rights \ reserved. \ The \ trademarks mentioned herein are the property of Biological \ Industries \ Israel \ Beit \ Haemek \ LTD. \ and/or its affiliates or their respective owners. \ BIUSA 0319A$ 

